On Wednesday the Food and Drug Administration approved something that would have read as science fiction a decade ago: a one-time treatment that edits a child's own cells to shut off sickle cell disease, now cleared for children as young as 2 [1].
The therapy is CASGEVY, and it has been available since 2023 - for patients 12 and older. Wednesday's decision drops that floor to age 2 for sickle cell disease with recurrent pain crises and for transfusion-dependent beta thalassemia, making it the first CRISPR-based gene-editing therapy ever approved for young children [1][3]. Roughly 5,500 American children became eligible overnight [2].
The mechanism is elegant enough to explain at a kitchen table. Doctors collect a child's own blood stem cells and use CRISPR to switch off a gene called BCL11A - the gene that tells the body to stop making fetal hemoglobin after infancy. With the switch off, the edited cells go back in and start producing fetal hemoglobin again, which does not sickle. The cells that caused the pain get outcompeted by cells that cannot [2].
The age floor matters more than it might sound. Sickle cell announces itself early - the first pain crises often arrive in toddlerhood - and every year of the disease is a year of accumulating damage to joints, organs, and childhoods spent in hospital beds. Under the old approval, a family with a 3-year-old diagnosis faced a nine-year wait while the damage compounded. That wait is gone [2].
The FDA cleared the expansion in 53 days under a new priority review pilot [1]. Honest caveats belong here: this is not a shot. The process runs months - cell collection, chemotherapy conditioning to make room for the edited cells, and a hospital stay - and it is demanding on small bodies. Families and their hematologists will weigh that against a lifetime of the disease.
The larger fact stands. A child born with sickle cell in America in 2024 no longer has to grow up with it.
